C.E Pharma
The computed 12-month bankruptcy probability of C.E Pharma is 7.3% (elevated). The 2023 annual accounts show negative equity (€-6k) and a net result of €-16k. The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €-6k |
| Net result | €-16k |
| Staff (FTE) | 0.5 |
| Active | 3 yrs |
Strong profile, led by profitability.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →| Fiscal year | 2023 |
|---|---|
| Revenue | - |
| EBITDA | €55k |
| Net profit | €-16k |
| Cash flow | €42k |
| Staff costs | €26k |
| Income taxes | €2 |
| Dividends | - |
| Total assets | €349k |
| Equity | €-6k |
| Debt | €355k |
| of which ≤ 1y | €109k |
| of which > 1y | €247k |
| Working capital | €-1k |
| Employees (FTE) | 0.5 |
| 2023 | |
|---|---|
| Current ratio | 0.99 |
| Quick ratio | 0.68 |
| Working capital ratio | -0.3% |
| Solvency | -1.8% |
| Debt / equity | -56.58 |
| Long-term debt ratio | -39.30 |
| Interest coverage | 4.15 |
| Gross margin | - |
| Net margin | - |
| ROA | -4.7% |
| ROE | 259.3% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2023 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €349k |
| Fixed assets | 21/28 | €242k |
| Intangible fixed assets | 21 | €121k |
| Tangible fixed assets | 22/27 | €121k |
| Financial fixed assets | 28 | €111 |
| Current assets | 29/58 | €107k |
| Stocks & contracts in progress | 3 | €33k |
| Amounts receivable within one year | 40/41 | €24k |
| Investments | 50/53 | €50k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €349k |
| Equity | 10/15 | €-6k |
| Contributions / capital | 10/11 | €10k |
| Accumulated profits (losses) | 14 | €-16k |
| Amounts payable | 17/49 | €355k |
| Amounts payable after one year | 17 | €247k |
| Amounts payable within one year | 42/48 | €109k |
| Trade debts payable within one year | 44 | €57k |
| Income statement | ||
| Gross operating margin | 9900 | €82k |
| Operating result | 9901 | €-3k |
| Financial income | 75 | €7 |
| Financial charges | 65 | €13k |
| Result before taxes | 9903 | €-16k |
| Income taxes | 67/77 | €2 |
| Net result for the period | 9904 | €-16k |
| Result to be appropriated | 9905 | €-16k |
| NACE primary | Retail trade(47730) |
| Legal form | Private limited company(610) |
| Incorporation | 08-11-2022 |
| Status | Active |
| Postal code | 1080 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21523B0937/00G086 | Brussels | 89 m² | 1 · 92 m² | 17.5 m · 4 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | C.E Pharma |